Cobra to manufacture Avidex anticancer product

Cobra Biomanufacturing, of Keele in the UK, has signed an agreement with Oxford-based biotech company Avidex for the manufacture of Avidex's lead anticancer product.

The programme of work includes process development, production and supply of GMP material through Phase I clinical trials.

This agreement offers Cobra an opportunity to participate in the development of Avidex's first product based on the use of soluble monoclonal T cell receptors. Cobra will use its expertise to develop a process and appropriate analytical methodology to manufacture the formulated product for clinical evaluation.

'Cobra is delighted to have the opportunity to apply its experience to this innovative product,' said David Thatcher, chief executive of Cobra Biomanufacturing.